With the support of


We lead global healthcare technology. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people. Medtronic. Engineering the extraordinary.


Stryker’s Neurovascular division is focused on advancing the practice of less invasive stroke therapies through its Complete Stroke Care solutions. It is dedicated to providing innovative stroke products and services for ischemic and hemorrhagic stroke, and is committed to providing clinical education and support to help physicians deliver better patient outcomes.


MicroVention is a rapidly growing company that has pioneered the development of minimally invasive neuroendovascular technologies that provide therapeutic advantages for neurovascular disorders.


Sim&Cure develops technology solutions to improve patient care, provide clinical education to expand knowledge and advance technology to make neurovascular treatments safer.


Balt has been collaborating with physicians for more than 45 years by providing them with differentiated and clinically relevant solution for the treatment of patients with neurovascular diseases.


Since 2005, Phenox has been dedicated to developing innovative, breakthrough and clinically proven solutions for the treatment of neurovascular diseases like ischemic and hemorrhagic stroke.

Siemens Healthineers

At Siemens Healthineers, our mission is to enable healthcare providers to increase their value by equipping them with innovative technologies and services in the areas of diagnostic and therapeutic imaging, endovascular robotics, laboratory diagnostics, and molecular medicine.


Philips is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum - from healthy living and prevention to diagnosis, treatment and home care. During the SLICE, Philips will showcase the Neurosuite solution that supports high levels of procedural efficiency to help and redefine outcomes for your neuro patients.


Asahi Intecc is a Japanese medical device company focused on delivering clinically unique devices such as guidewires, micro catheters and guiding catheters used in vascular procedures. Our neuro-vascular line-up includes CHIKAI guide wires (size between 0.008''- 0.018'') and FUBUKI guiding catheters.


Sonorous is a medical device company focused on delivering innovative solutions to treat patients suffering from debilitating symptomatic cerebral venous diseases.


In the simplest sense, we’re a company that creates solutions. More specifically, we design novel access device technology for vascular interventions and unmet clinical needs. Because in the precious seconds that surround a stroke emergency, clinicians need technology that delivers. That’s where we come in.


Galaxy Therapeutics, an emerging medical device manufacturer based in Milpitas, California, is focused on the development of saccular flow disrupting devices for cerebral aneurysm treatment to achieve rapid dome thrombosis with increased safety and ease of use.


Cerus Endovascular is a privately owned medical device company based in Fremont, California and Oxford, United Kingdom. We design, develop, manufacture and supply complex flow diverting and flow disrupting products used by Interventional Neuroradiologists for the treatment of haemorrhagic stroke.


The Bendit Microcatheter® is a unique transformative endovascular navigation technology that introduces a “articulating” function and 1:1 torquability, This allows doctors to steer and control the tip with 360° multiplanar rotation.

The Brain Aneurysm Foundation

The Brain Aneurysm Foundation is a non-profit organization that represents the interests of current and future patients. We educate society about brain aneurysms, their symptoms, and treatment options. We believe publicizing the information about brain aneurysms and treatments helps save lives.


Want to become a partner ?

Join us and participate in the practical training of practitioners in neuroscience, neurology, neurosurgery and neuroradiology.